Form 4: Teradyne Executive Regan Mills Receives Equity Grant

Teradyne's President of Product Test, Regan Mills, was granted 1,004 restricted stock units and 886 stock options, aligning executive interests with shareholder value.

Summary

• Regan Mills, President, Product Test at Teradyne, Inc., received an equity grant on February 4, 2026.
• The grant includes 1,004 Restricted Stock Units (RSUs) under the company's 2006 Equity and Cash Compensation Incentive Plan.
• Each RSU represents the right to receive one share of Common Stock.
• These RSUs will vest in four equal annual installments, commencing on February 4, 2027.
• Additionally, Mills was granted 886 stock options with an exercise price of $269.07.
• These stock options have an expiration date of February 4, 2033.
• The stock options will vest 25% per year over four years, also beginning on February 4, 2027.
• Following these transactions, Mills beneficially owns 12,677.3452 shares of Common Stock and 886 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management's financial interests with the company's long-term success, which is generally favorable for shareholders.

Positives

• Granting of equity to a key executive, Regan Mills, aligns management's interests with long-term shareholder value.
• The equity awards incentivize the President of Product Test to contribute to the company's sustained growth and performance.
• The vesting schedule encourages long-term commitment and retention of key talent.

Negatives

• The equity grants, particularly the RSUs, represent potential future dilution for existing shareholders as shares are issued upon vesting.
• The stock options' value is dependent on the future stock price exceeding the exercise price of $269.07, introducing market risk.

Risks

• Future dilution of existing shareholders upon the vesting and conversion of RSUs into common stock.
• The value of the stock options is subject to market fluctuations and may not be realized if the stock price does not exceed the exercise price.
• The long vesting period means the executive's compensation is tied to future company performance, which carries inherent business risks.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend over four years, beginning February 4, 2027, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that equity grants to key executives like Regan Mills are a standard practice in the technology and semiconductor equipment industry, aiming to align leadership incentives with long-term company performance and shareholder returns. This practice is common among peers like Applied Materials (AMAT) and KLA Corporation (KLAC), where executive compensation packages frequently include significant equity components to foster retention and drive strategic objectives.

Comparison to Industry Standards

• The structure of granting both RSUs and stock options is a common compensation strategy for senior executives in the technology sector, similar to practices at companies like Intel or NVIDIA.
• The four-year vesting schedule for both RSUs and stock options is a standard industry practice designed to encourage long-term executive retention and performance, comparable to vesting periods seen at companies such as Qualcomm and Broadcom.
• The exercise price of $269.07 for the stock options reflects the market price at the time of grant, a typical approach for incentive stock options.

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned executive incentives, but also potential future dilution from RSU conversion.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.
• Management: Direct financial incentive tied to company performance and stock appreciation.

Next Steps

• The RSUs will vest in four equal annual installments starting February 4, 2027.
• The stock options will vest 25% per year over four years, also beginning February 4, 2027.
• The stock options can be exercised at $269.07 per share until their expiration on February 4, 2033.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for Teradyne. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Teradyne, TER, Regan Mills, Form 4, SEC filing, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Beneficial Ownership, Corporate Governance